INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 179 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2021. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $961,061 | -17.5% | 18,450 | +0.3% | 0.00% | 0.0% |
| Q2 2023 | $1,164,645 | +24.0% | 18,393 | +6.0% | 0.00% | 0.0% |
| Q1 2023 | $939,448 | -9.5% | 17,349 | -11.6% | 0.00% | -25.0% |
| Q4 2022 | $1,038,396 | +23.6% | 19,622 | +8.9% | 0.00% | +33.3% |
| Q3 2022 | $840,000 | -16.6% | 18,025 | +2.2% | 0.00% | 0.0% |
| Q2 2022 | $1,007,000 | -33.2% | 17,638 | -28.4% | 0.00% | 0.0% |
| Q1 2022 | $1,507,000 | +7.0% | 24,633 | -8.5% | 0.00% | 0.0% |
| Q4 2021 | $1,408,000 | +42.8% | 26,913 | +1.8% | 0.00% | 0.0% |
| Q3 2021 | $986,000 | -26.6% | 26,437 | -19.7% | 0.00% | -25.0% |
| Q2 2021 | $1,344,000 | +37.0% | 32,924 | +13.8% | 0.00% | +33.3% |
| Q1 2021 | $981,000 | +13.9% | 28,924 | +6.9% | 0.00% | 0.0% |
| Q4 2020 | $861,000 | +77.9% | 27,061 | +43.5% | 0.00% | +50.0% |
| Q3 2020 | $484,000 | +4.3% | 18,858 | +4.2% | 0.00% | 0.0% |
| Q2 2020 | $464,000 | +149.5% | 18,094 | +49.7% | 0.00% | +100.0% |
| Q1 2020 | $186,000 | -69.9% | 12,088 | -32.8% | 0.00% | -66.7% |
| Q4 2019 | $617,000 | +314.1% | 17,988 | -10.1% | 0.00% | +200.0% |
| Q3 2019 | $149,000 | -44.8% | 20,010 | -4.0% | 0.00% | -50.0% |
| Q2 2019 | $270,000 | -5.9% | 20,835 | -11.7% | 0.00% | 0.0% |
| Q1 2019 | $287,000 | +8.3% | 23,594 | +1.4% | 0.00% | 0.0% |
| Q4 2018 | $265,000 | -56.1% | 23,276 | -16.2% | 0.00% | -50.0% |
| Q3 2018 | $603,000 | +18.2% | 27,791 | -3.8% | 0.00% | +33.3% |
| Q2 2018 | $510,000 | -20.9% | 28,884 | -5.8% | 0.00% | -25.0% |
| Q1 2018 | $645,000 | +24.8% | 30,661 | -14.1% | 0.00% | 0.0% |
| Q4 2017 | $517,000 | +22.2% | 35,705 | +33.3% | 0.00% | 0.0% |
| Q3 2017 | $423,000 | +34.7% | 26,776 | +6.0% | 0.00% | +33.3% |
| Q2 2017 | $314,000 | -28.5% | 25,269 | -6.6% | 0.00% | -40.0% |
| Q1 2017 | $439,000 | -14.8% | 27,045 | -20.7% | 0.01% | -16.7% |
| Q4 2016 | $515,000 | +146.4% | 34,098 | +778.6% | 0.01% | +100.0% |
| Q4 2015 | $209,000 | – | 3,881 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |